Optimizing a lupus autoantibody for targeted cancer therapy

Area of Science:

• Immunology
• Oncology
• Molecular Biology

Background:

• Antibody-based cancer therapies offer specificity but struggle with intracellular targeting.
• Lupus autoantibodies have demonstrated the ability to penetrate cell nuclei.
• The therapeutic potential of lupus autoantibodies in cancer is an emerging field.

Purpose of the Study:

• To investigate the efficacy of modified lupus autoantibody fragments for cancer therapy.
• To determine if these autoantibodies can selectively target and induce toxicity in cancer cells.

Main Methods:

• Utilized a divalent lupus anti-DNA autoantibody fragment engineered for enhanced nuclear penetration and DNA binding.
• Assessed the impact of the antibody fragment on DNA double-strand breaks in cancer cells.
• Evaluated the selective toxicity of the antibody fragment against cancer cells and tumors with deficient homology-directed repair.

Main Results:

• The engineered lupus autoantibody fragment successfully penetrated cell nuclei and bound to DNA.
• Treatment with the antibody fragment led to an accumulation of DNA double-strand breaks in cancer cells.
• The antibody fragment exhibited high and selective toxicity towards cancer cells and tumors with defective homology-directed repair.

Conclusions:

• Optimized lupus autoantibodies can be effectively utilized to induce DNA damage and selectively kill cancer cells.
• These findings provide proof of principle for employing lupus autoantibodies in targeted cancer therapy, particularly for tumors with specific DNA repair defects.